NMD-VCell Neuromuscular Virtual Cell Research Platform Module: Design · Evidence → perturbation → experiment → outcome NMD = neuromuscular disorders

Release 2026.08DMD context observedDMD candidate-conditioned prediction not yet eligible

View scientific status
Evidence freeze: 3 August 2026 Resource: v1.2.0-measured-dmd-evidence Schema: 1.1 Open release status →

Plan an experiment

Study design

Turn one candidate decision into a predeclared experiment.

Search a gene. For the 21 governed candidates, the planner loads the released decision contract, prefills the question and assay route, and requires human confirmation before generating a draft. It does not rank candidates or upgrade evidence levels.

Step 1 of 5

Selected gene: MON1A. Current evidence level: L2 (first arm). Blocking gap: GAP-02. Recommended route: Muscle-context assay.

Recommended examples: ZNF133 · CPEB1 · GFOD2.

Module meaning contract

Design · what this module can change

See all eight modules →
Question answeredWhat falsifiable experiment would close the named evidence gap and what result would change the decision?
Scope & evidence unitVersioned Study Cards currently cover the 21 governed DMD candidates. Other disease modules provide bounded next-experiment recommendations, not registered Study Cards.One versioned Study Card with estimand, endpoint, replication, QC, analysis and stopping rule.
ProducesA downloadable draft design object with explicit registration gaps and links to its evidence inputs.
Cannot establishA draft is not a registered study, executed experiment, measured outcome, target validation or efficacy result.

Next handoffInspect lifecycle state in Registry; registration and execution remain prospective. Continue →

Product contract · WORKFLOW-OUTCOME-CARD-1.0

Workflow Card: What experiment can change the conclusion?

EstimandContext · dose · timeBiological unitControls + endpointsQC + decision ruleOutcome return

Five-step experiment planner

Answer four more questions to create a Study Card.

What this means: candidate-specific fields are prefilled from the released decision contract. You can refine the cell model and endpoint, but the exported draft preserves the original contract and its result rules.

Planner visual builder

Turn one gene into a bounded experiment route.

The planner is a preregistration-style experimental workflow: it resolves a gene, shows the frozen evidence state, exposes the blocking gap, selects the current assay route and lists the registration fields still open.

BoundaryThis builder does not rank candidates, change evidence levels, compute target scores, infer therapeutic direction or make disease-prediction claims.
Draft Study Cards21versioned Study Cards
Action classes5current next-step categories
L3b replications0same-perturbation evidence absent
Prediction statusP0P1/P2 remain locked
1Resolve geneHGNC identifier and typed record
2Evidence stateL1/L2/L3a fields only
3Blocking gapgap code stays explicit
4Assay routeaction-specific scaffold
5Register draftrequires frozen fields

Current Study Card action map

Test in human myogenic cells2 Study Cards
Run an independent human myogenic perturbation experiment.
Confirm the gene is detectable4 Study Cards
Confirm target detectability before perturbation escalation.
Review safety and biological context7 Study Cards
Resolve dependency, toxicity or context risks before escalation.
Reproduce the result independently7 Study Cards
Repeat the source-state analysis in an independent frozen workflow.
Pause until external evidence is audited1 Study Card
Import and audit the reported external evidence before changing state.

Shared planner link restored on the server

Selected gene: MON1A

L2
HGNCHGNC:28207
Current evidence levelL2
Blocking gapGAP-02Independent muscle-context perturbation is absent
Recommended routeMuscle-context assay
Comparison objectCMP-20260726-A04D03258188
Planner objectPLN:v1.2.0-measured-dmd-evidence:MON1A:1.0-DRAFT
Study Card objectSC:v1.2.0-measured-dmd-evidence:MON1A:1.5-DRAFT
Outcome slotOUT:v1.2.0-measured-dmd-evidence:MON1A:PENDING

Selected gene: MON1A. Current evidence level: L2 (first arm). Blocking gap: GAP-02. Recommended route: Muscle-context assay. Object trace: CMP-20260726-A04D03258188 → PLN:v1.2.0-measured-dmd-evidence:MON1A:1.0-DRAFT → SC:v1.2.0-measured-dmd-evidence:MON1A:1.5-DRAFT → OUT:v1.2.0-measured-dmd-evidence:MON1A:PENDING.

Candidate decision contract restored on the server

MON1A · review before creating a draft

GAP-02
Research questionDoes the MON1A response observed outside muscle transfer to a controlled human myogenic system?
Decision available nowEligible for a preregistered human-myogenic feasibility experiment; not established as a therapeutic target.
Decision-blocking gapGAP-02 · Independent muscle-context perturbation is absent
Minimum next actionPerturb MON1A with at least two independent reagents in a declared human myogenic state and freeze one functional primary endpoint.
Result-to-decision rules

Concordant / feasibleIf engagement and QC pass, both reagents agree, and the primary phenotype replicates beyond one biological unit, advance to matched DMD/control validation.

Equivalent null / stopIf engagement and QC pass but the primary phenotype is null, record a null muscle-context outcome and stop treating the non-muscle response as transferable.

Not evaluable / QC failureIf reagents, donors or batches disagree, classify the result as inconclusive and resolve heterogeneity before any escalation.

Confirmation required: the interactive planner prefills these fields but will not create a candidate draft until the researcher confirms this contract.

Stable governed records

Versioned Study Cards grouped by current action

All 21 routes are static, shareable and tied to v1.2.0-measured-dmd-evidence, schema 1.1 and build EA-20260817-57. JSON, YAML and TSV exports are available on every card.

Test in human myogenic cells

2 Study Cards

Run an independent human myogenic perturbation experiment.

2

Confirm the gene is detectable

4 Study Cards

Confirm target detectability before perturbation escalation.

4

Review safety and biological context

7 Study Cards

Resolve dependency, toxicity or context risks before escalation.

7

Reproduce the result independently

7 Study Cards

Repeat the source-state analysis in an independent frozen workflow.

7

Pause until external evidence is audited

1 Study Card

Import and audit the reported external evidence before changing state.

1